experimental group:Camrelizumab combined with radiotherapy

3 trials

Sponsors

Affiliated Tumor Hospital of Zhengzhou University, Department of radiotherapy, Changzhou Second People's Hospital, Affiliated Cancer Hospital of Harbin Medical University

Conditions

Advanced non-small cell lung cancerEsophageal squamous cell carcinomaUndifferentiated pleomorphic sarcoma

Phase 2

A single-center, randomized, controlled phase II clinical study of carillizumab combined with preoperative radiotherapy for resectable undifferentiated pleomorphic sarcoma

RecruitingChiCTR1900027356

Affiliated Tumor Hospital of Zhengzhou UniversityUndifferentiated pleomorphic sarcoma

Start: 2019-11-10Updated: 2019-11-11

A prospective, multicenter, randomized, controlled, phase II trial for comparing Camrelizumab combined radiotherapy and concurrent chemoradiotherapy in the treatment of unresectable locally advanced esophageal squamous cell carcinoma

Active, not recruitingChiCTR2000033308

Department of radiotherapy, Changzhou Second People's HospitalEsophageal squamous cell carcinoma

Start: 2020-06-30Updated: 2020-06-01

An open clinical study of Camrelizumab combined with radiotherapy in the treatment of advanced non-small cell lung cancer

RecruitingChiCTR2000039895

Affiliated Cancer Hospital of Harbin Medical UniversityAdvanced non-small cell lung cancer

Start: 2020-11-18Updated: 2021-02-22